| 摘要: |
| 为持续探索完善我国基于风险启动药品注册核查的工作方法,本文对美国药品检查相关的机构和法规文件,以及批准前检查和监督检查的工作程序等进行了阐述,通过对比分析我国在实施基于风险的药品注册核查工作中存在的不足,并提出具体建议,促进我国基于风险的药品注册核查更加科学和规范化。 |
| 关键词: 基于风险 药品检查 注册核查 对比分析 |
| DOI:10.13506/j.cnki.jpr.2024.01.017 |
| 基金项目: |
|
Publication Date:January 25, 2024
|
|
| A comparative study of risk-based drug inspection between NMPA and US FDA |
| LI Yuan,ZHOU Gang |
| (Center for Drug Evaluation,National Medical Products Administration,Beijing 100076,China) |
| Abstract: |
| In order to continue to explore and improve the working methods of risk-based drug inspection in China, this paper describes the institutions, regulatory documents and implementation procedures related to drug inspection in the United States, and analyzes the shortcomings in the implementation of risk-based drug registration inspection in China through comparison. Some specific suggestions are put forward to promote the more scientific and standardized risk-based drug registration inspection in our country. |
| Key words: Risk-based Drug inspection Registration Comparison and analysis |